Pfizer has distributed $49 billion in payouts to shareholders, yet its stock has significantly underperformed the broader market. This analysis explores the trade-off between substantial shareholder returns and the pharmaceutical giant's lagging equity valuation.
Pfizer's $49 Billion Payouts Contrast With Lagging Stock Performance
|1 min read
PFEpharmaceuticalsdividendsstock performanceshareholder value
